Jackisch, C; Kim, S-B; Semiglazov, V; Melichar, B; Pivot, X; Hillenbach, C; Stroyakovskiy, D; Lum, B L; Elliott, R; Weber, H A; Ismael, G
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2015Feb ; 26 ( 2 ) :320-5.
PMID : 25403587
ÀúÀÚ »ó¼¼Á¤º¸
Jackisch, C - Department of Obstetrics and Gynecology and Breast Cancer and Gynecology Cancer Center, Sana Klinikum Offenbach GmbH, Offenbach, Germany christian.jackisch@sana.de.
Kim, S-B - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Semiglazov, V - Department of Surgery, NN Petrov Research Institute of Oncology, St Petersburg, Russia.
Melichar, B - Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
Pivot, X - Chemotherapy-Oncology, CHU Jean Minjoz, Besancon, France.
Hillenbach, C - Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Stroyakovskiy, D - Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russia.
Lum, B L - Clinical Pharmacology.
Elliott, R - BioAnalytical Sciences, Genentech, South San Francisco, USA.
Weber, H A - Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ismael, G - Hospital Amaral Carvalho, Jau, Brazil.
ABSTRACT
BACKGROUND: HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months. PATIENTS AND
METHODS: Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out.
RESULTS: s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure.
CONCLUSIONS: Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups. CLINICAL TRIAL NUMBER: NCT00950300. CI - ??The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
keyword
HER2/neu; breast cancer; chemotherapy; neoadjuvant; subcutaneous; trastuzumab
MESH
Adult, Antineoplastic Agents/*administration & dosage/adverse effects/pharmacokinetics, Breast Neoplasms/*drug therapy/genetics, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Middle Aged, Receptor, ErbB-2/biosynthesis/genetics, Trastuzumab/*administration & dosage/adverse effects
¸µÅ©